Bluetop Co.,Ltd. (XKON:191600)
South Korea · Delayed Price · Currency is KRW 7,010.00
-180.00 (-2.50%)
At close: Jul 29, 2025, 3:30 PM KST
Verve Therapeutics Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | 2006 - 2010 |
|---|---|---|---|---|---|---|
Period Ending | Dec '15 Dec 31, 2015 | Dec '14 Dec 31, 2014 | Dec '13 Dec 31, 2013 | Dec '12 Dec 31, 2012 | Dec '11 Dec 31, 2011 | 2006 - 2010 |
| 25,842 | 13,572 | 17,704 | 15,053 | 16,724 | Upgrade | |
Revenue Growth (YoY) | 90.41% | -23.34% | 17.61% | -9.99% | -7.43% | Upgrade |
Cost of Revenue | 20,881 | 10,823 | 14,882 | 14,102 | 15,271 | Upgrade |
Gross Profit | 4,961 | 2,749 | 2,822 | 950.91 | 1,453 | Upgrade |
Selling, General & Admin | 2,143 | 947.56 | 1,680 | 1,159 | 1,317 | Upgrade |
Research & Development | 467.21 | 146.36 | 263.75 | 253.39 | 225.51 | Upgrade |
Other Operating Expenses | -32.12 | 20.94 | -108.25 | 36.93 | 18.04 | Upgrade |
Operating Expenses | 2,773 | 1,430 | 2,101 | 1,884 | 1,726 | Upgrade |
Operating Income | 2,188 | 1,319 | 721.2 | -932.7 | -272.74 | Upgrade |
Interest Expense | -272.62 | -407.87 | -320.14 | -637.68 | -349.91 | Upgrade |
Interest & Investment Income | 3.12 | 2.32 | 17.44 | 1.45 | 25.05 | Upgrade |
Earnings From Equity Investments | - | 965.54 | - | - | - | Upgrade |
Currency Exchange Gain (Loss) | 68.59 | 43.14 | 24.12 | 28.63 | -40.03 | Upgrade |
Other Non Operating Income (Expenses) | 532.84 | 351.61 | -891.64 | 146.94 | 1,643 | Upgrade |
EBT Excluding Unusual Items | 2,520 | 2,274 | -449.02 | -1,393 | 1,006 | Upgrade |
Gain (Loss) on Sale of Investments | - | -39.99 | - | - | - | Upgrade |
Gain (Loss) on Sale of Assets | 83.96 | 5 | 10.67 | 38.34 | - | Upgrade |
Other Unusual Items | - | - | 1,572 | -34.27 | 2,946 | Upgrade |
Pretax Income | 2,604 | 2,239 | 1,134 | -1,389 | 3,951 | Upgrade |
Income Tax Expense | 17.57 | - | - | - | - | Upgrade |
Net Income | 2,586 | 2,239 | 1,134 | -1,389 | 3,951 | Upgrade |
Net Income to Common | 2,586 | 2,239 | 1,134 | -1,389 | 3,951 | Upgrade |
Net Income Growth | 15.53% | 97.43% | - | - | - | Upgrade |
Shares Outstanding (Basic) | 0 | 2 | 0 | 0 | 0 | Upgrade |
Shares Outstanding (Diluted) | 0 | 2 | 0 | 0 | 0 | Upgrade |
Shares Change (YoY) | -86.07% | 995.65% | 70.42% | -47.63% | -4.52% | Upgrade |
EPS (Basic) | 9947.03 | 1199.00 | 6654.03 | -13893.13 | 20692.07 | Upgrade |
EPS (Diluted) | 9947.03 | 1199.00 | 6654.03 | -13893.13 | 20692.07 | Upgrade |
EPS Growth | 729.61% | -81.98% | - | - | - | Upgrade |
Free Cash Flow | -1,168 | 172.01 | 1,184 | 693.82 | 409.66 | Upgrade |
Free Cash Flow Per Share | -4491.72 | 92.12 | 6948.84 | 6938.24 | 2145.31 | Upgrade |
Gross Margin | 19.20% | 20.25% | 15.94% | 6.32% | 8.69% | Upgrade |
Operating Margin | 8.47% | 9.72% | 4.07% | -6.20% | -1.63% | Upgrade |
Profit Margin | 10.01% | 16.50% | 6.40% | -9.23% | 23.63% | Upgrade |
Free Cash Flow Margin | -4.52% | 1.27% | 6.69% | 4.61% | 2.45% | Upgrade |
EBITDA | 2,781 | 1,918 | 1,089 | -511.22 | 454.35 | Upgrade |
EBITDA Margin | 10.76% | 14.13% | 6.15% | -3.40% | 2.72% | Upgrade |
D&A For EBITDA | 593.07 | 598.73 | 367.41 | 421.49 | 727.08 | Upgrade |
EBIT | 2,188 | 1,319 | 721.2 | -932.7 | -272.74 | Upgrade |
EBIT Margin | 8.47% | 9.72% | 4.07% | -6.20% | -1.63% | Upgrade |
Effective Tax Rate | 0.68% | - | - | - | - | Upgrade |
Advertising Expenses | 2.09 | 3.33 | 2.25 | - | 3.7 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.